Ellen Kampman, at Wageningen University and Research Centre (Netherlands), looked at whether selenium is able to induce changes in the cells of the prostate and if these changes might be relevant to the prevention of prostate cancer.
The research found preliminary evidence that selenium might prevent inflammation in the prostate, but to what extent the prevention of inflammation decreases risk of prostate cancer remains unclear. It was also observed that selenium might be able to interfere in a process that subtly changes the characteristics of prostate cells; the relevance of this finding with respect to prostate cancer warrants further research.
Par Stattin, at Umea University in Sweden, explored whether high levels of B12 and folate (crucial components of one-carbon metabolism) are associated with an increased risk of prostate cancer.
This research found an association between high levels of vitamin B12 and the risk of advanced prostate cancer. It also found some modest but statistically significant associations between choline and vitamin B2 and risk of prostate cancer.
Richard Martin, at the University of Bristol (England), examined whether vitamin D protects against prostate cancer.
The research findings strengthen the evidence that high levels of vitamin D may protect against more aggressive prostate cancer. This observed association indicates the potential role for vitamin D manipulation to control the progression of prostate cancer.
Stephanie Smith-Warner, at the Harvard School of Public Health (USA), examined the links between several dietary factors and the risk of prostate cancer.
This research found red meat, processed meat and egg consumption were associated with higher risks of advanced prostate cancer. Poultry consumption was associated with a lower risk of advanced prostate cancer. Fruit and vegetable intakes were not associated with advanced prostate cancer risk.
Intakes of red meat, processed meat, seafood (fish and shellfish combined), poultry, and eggs were not associated with higher or lower risk of localised prostate cancer.